

Thomas K Doktor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4940712/publications.pdf>

Version: 2024-02-01

25
papers

1,165
citations

567281

15
h-index

580821

25
g-index

27
all docs

27
docs citations

27
times ranked

2165
citing authors

#	ARTICLE	IF	CITATIONS
1	Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	189
2	Splicing factor 1 modulates dietary restriction and TORC1 pathway longevity in <i>C. elegans</i> . <i>Nature</i> , 2017, 541, 102-106.	27.8	152
3	CUGBP1 and MBNL1 preferentially bind to 3' UTRs and facilitate mRNA decay. <i>Scientific Reports</i> , 2012, 2, 209.	3.3	150
4	Seemingly Neutral Polymorphic Variants May Confer Immunity to Splicing-Inactivating Mutations: A Synonymous SNP in Exon 5 of MCAD Protects from Deleterious Mutations in a Flanking Exonic Splicing Enhancer. <i>American Journal of Human Genetics</i> , 2007, 80, 416-432.	6.2	140
5	RNA-sequencing of a mouse-model of spinal muscular atrophy reveals tissue-wide changes in splicing of U12-dependent introns. <i>Nucleic Acids Research</i> , 2017, 45, 395-416.	14.5	87
6	Global identification of hnRNP A1 binding sites for SSO-based splicing modulation. <i>BMC Biology</i> , 2016, 14, 54.	3.8	62
7	DeepCLIP: predicting the effect of mutations on protein-RNA binding with deep learning. <i>Nucleic Acids Research</i> , 2020, 48, 7099-7118.	14.5	54
8	The deep intronic c.903+469T>C mutation in the <i>MTRR</i> gene creates an SF2/ASF binding exonic splicing enhancer, which leads to pseudoexon activation and causes the cbIE type of homocystinuria. <i>Human Mutation</i> , 2010, 31, 437-444.	2.5	53
9	SMN2 exon 7 splicing is inhibited by binding of hnRNP A1 to a common ESS motif that spans the 3' splice site. <i>Human Mutation</i> , 2011, 32, 220-230.	2.5	41
10	The <i>ETFDH</i> c.158A>G Variation Disrupts the Balanced Interplay of ESE- and ESS-Binding Proteins thereby Causing Missplicing and Multiple Acyl-CoA Dehydrogenation Deficiency. <i>Human Mutation</i> , 2014, 35, 86-95.	2.5	32
11	Splice-shifting oligonucleotide (SSO) mediated blocking of an exonic splicing enhancer (ESE) created by the prevalent c.903+469T>C <i>MTRR</i> mutation corrects splicing and restores enzyme activity in patient cells. <i>Nucleic Acids Research</i> , 2015, 43, 4627-4639.	14.5	28
12	The phenylalanine hydroxylase c.30C>G synonymous variation (p.G10G) creates a common exonic splicing silencer. <i>Molecular Genetics and Metabolism</i> , 2010, 100, 316-323.	1.1	23
13	The prevalent deep intronic c. 639 + 919 G > A <i>GLA</i> mutation causes pseudoexon activation and Fabry disease by abolishing the binding of hnRNPA1 and hnRNP A2/B1 to a splicing silencer. <i>Molecular Genetics and Metabolism</i> , 2016, 119, 258-269.	1.1	23
14	A synonymous polymorphic variation in <i>ACADM</i> exon 11 affects splicing efficiency and may affect fatty acid oxidation. <i>Molecular Genetics and Metabolism</i> , 2013, 110, 122-128.	1.1	22
15	Pseudoexon activation in disease by non-splice site deep intronic sequence variation – wild type pseudoexons constitute high-risk sites in the human genome. <i>Human Mutation</i> , 2022, 43, 103-127.	2.5	17
16	Next generation sequencing of RNA reveals novel targets of resveratrol with possible implications for Canavan disease. <i>Molecular Genetics and Metabolism</i> , 2019, 126, 64-76.	1.1	16
17	Blocking of an intronic splicing silencer completely rescues <i>IKBKAP</i> exon 20 splicing in familial dysautonomia patient cells. <i>Nucleic Acids Research</i> , 2018, 46, 7938-7952.	14.5	15
18	Identification of <i>SRSF10</i> as a regulator of <i>SMN2</i> ISS. <i>Human Mutation</i> , 2021, 42, 246-260.	2.5	15

#	ARTICLE	IF	CITATIONS
19	Vulnerable exons, like <i>ACADM</i> exon 5, are highly dependent on maintaining a correct balance between splicing enhancers and silencers. <i>Human Mutation</i> , 2022, 43, 253-265.	2.5	11
20	Antisense Oligonucleotide Rescue of Deep-Intronic Variants Activating Pseudoexons in the 6-Pyruvoyl-Tetrahydropterin Synthase Gene. <i>Nucleic Acid Therapeutics</i> , 2022, 32, 378-390.	3.6	7
21	VEGFA-targeting miR-agshRNAs combine efficacy with specificity and safety for retinal gene therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 58-76.	5.1	6
22	DFI-seq identification of environment-specific gene expression in uropathogenic <i>Escherichia coli</i> . <i>BMC Microbiology</i> , 2017, 17, 99.	3.3	5
23	Down-regulation of CK2 \pm correlates with decreased expression levels of DNA replication minichromosome maintenance protein complex (MCM) genes. <i>Scientific Reports</i> , 2019, 9, 14581.	3.3	5
24	Absence of an Intron Splicing Silencer in Porcine <i>Smn1</i> Intron 7 Confers Immunity to the Exon Skipping Mutation in Human <i>SMN2</i> . <i>PLoS ONE</i> , 2014, 9, e98841.	2.5	4
25	Essential role of CK2 \pm for the interaction and stability of replication fork factors during DNA synthesis and activation of the S-phase checkpoint. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	2